Investigational drug · Phase 2
TNP-2092
Also called: rifaquizinone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prosthetic Joint Infection (PJI), Periprosthetic Joint Infection (PJI).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "TNP-2092"
First trial start
2025
Apr 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TNP-2092", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prosthetic Joint Infection (PJI)
- Periprosthetic Joint Infection (PJI)
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TNP-2092" as an intervention, largest first.
- TNP-2092 to Treat Acute Bacterial Skin and Skin Structure InfectionPivotal-lookingCompleted
TenNor Therapeutics LimitedIndustry
NCT03964493 · 120 participants · Start Apr 20, 2019 · Primary completion Sep 28, 2020
Drug: TNP-2092; Vancomycin · For: Skin and Subcutaneous Tissue Bacterial Infections; Gram-Positive Bacterial Infections
Sites: San Diego, California
- A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 CapsulesCompleted
TenNor Therapeutics (Suzhou) LimitedIndustry
NCT06178718 · 58 participants · Start Jun 6, 2016 · Primary completion Aug 2, 2016
Drug: TNP-2092 capsules; TNP-2092 placebo capsules · For: Hyperammonemia
Sites: Changchun, China
TenNor Therapeutics (Zhongshan) LimitedIndustry
NCT07858916 · 40 participants (planned) · Start Oct 21, 2026 · Primary completion Sep 2027
Drug: TNP-2092 for injection; Vancomycin Hydrochloride for Injection and 2 more · For: Prosthetic Joint Infection (PJI)
Sites: Ürümqi, China
TenNor Therapeutics (Suzhou) LimitedIndustry
NCT06190340 · 40 participants · Start Nov 8, 2016 · Primary completion Sep 26, 2017
Drug: TNP-2092 capsules; Placebo · For: Helicobacter Pylori Infection
Sites: Changchun, China
TenNor Therapeutics (Suzhou) LimitedIndustry
NCT06135675 · 36 participants · Start Aug 27, 2020 · Primary completion Jun 16, 2021
Drug: TNP-2092 capsules; Placebo · For: Hyperammonemia
Sites: Changchun, China
TenNor Therapeutics Inc.Industry
NCT06889701 · 33 participants (planned) · Start Apr 3, 2025 · Primary completion Jan 2027
Drug: TNP-2092 for injection; Vancomycin Hydrochloride for Injection (IA) and 3 more · For: Periprosthetic Joint Infection (PJI)
Sites: Ürümqi, China
TenNor Therapeutics Inc.Industry
NCT06394518 · 32 participants · Start Jul 7, 2022 · Primary completion Feb 24, 2023
Drug: TNP-2092 for injection; placebo · For: Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Prosthetic Joints Infection (PJI)
Sites: Shanghai, China
TenNor Therapeutics Inc.Industry
NCT06337604 · 20 participants · Start Oct 10, 2017 · Primary completion Nov 23, 2017
Drug: TNP-2092 capsules; TNP-2092 capsules placebo and 1 more · For: Helicobacter Pylori Infection
Sites: Changchun, China
TenNor Therapeutics LimitedIndustry
NCT04294862 · 13 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2021
Drug: TNP-2092 · For: Prosthetic Joint Infection
Sites: Philadelphia, Pennsylvania
TenNor Therapeutics LimitedIndustry
NCT05074134 · 6 participants · Start Oct 16, 2021 · Primary completion Nov 30, 2021
Drug: [14C]-TNP-2092 · For: Healthy
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug.
Lu M, Chen J, Zhang H, et al. · Expert Opin Investig Drugs 2026
- The Efficacy and Safety of an Intra-articular Dual-Acting Antibacterial Agent (TNP-2092) for Implant Infection-Associated Methicillin-Resistant Staphylococcus aureus.
Dai T, Ma C, Zhang F, et al. · J Infect Dis 2024
- A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198.
Nazli A, He DL, Xu H, et al. · Curr Med Chem 2022
- Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.
Surur AS, Sun D · Front Chem 2021
- Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data.
Boyanova L, Markovska R, Hadzhiyski P, et al. · Future Microbiol 2020
- In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci.
Fisher CR, Schmidt-Malan SM, Ma Z, et al. · Diagn Microbiol Infect Dis 2020
Also in development for Prosthetic Joint Infection (PJI)
- antibioticsPhase 23 trials
TenNor Therapeutics (Zhongshan) Limited · Prosthetic Joint Infection (PJI), Periprosthetic Joint Infection (PJI), Acute Pyelonephritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.